Tak Paul Peter's Form 4 filing
Candel Therapeutics, Inc. (CADL) · filed Mar 20, 2025
- Accession no.
- 0000950170-25-042725
- Filed
- Mar 20, 2025
- Trade date
- Mar 18-19, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $229.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tak Paul PeterCIK 0001873905 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 18, 2025 | Common Stock | SSaleDisposed | −25,772 | $8.77 | −$226,020.44 | 226,140 | Direct | |
| Mar 19, 2025 | Common Stock | SSaleDisposed | −400 | $9.00 | −$3,600 | 225,740 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.